Nader Z. Pourhassan, Ph.D., the president and CEO of CytoDyn
(OTCQB: CYDY), was recently interviewed by TWST.com. The interview was highlighted in a recent article
titled, “CytoDyn About to Take Off? CEO Nader Pourhassan Ph. D. Says Yes,”
which provided an overview of the biotechnology company from the perspective of
its president & CEO. Dr. Pourhassan discussed the rapid clinical
development of PRO 140 which is being developed as a therapy for HIV. He has
overseen PRO 140 from its acquisition to phase II development and phase III
trials. In addition, Dr. Pourhassan has been involved in the preclinical and
clinical development of PRO 140 in other immunological indications and cancer.
“In regard to monotherapy, PRO 140 could allow patients to put away all their
pills. We have a small group of patients right now who have gone four years
without pills with PRO 140 as a monotherapy. It takes between 30 seconds and
two minutes once a week to subcutaneously self-inject themselves at home, and
that is all they need,” CytoDyn president and CEO Nader Z. Pourhassan, Ph.D.
stated in the interview.
To view the full article, visit http://ibn.fm/Xtcaz
About CytoDyn
CytoDyn is a biotechnology company developing innovative
treatments for multiple therapeutic indications based on PRO 140 (leronlimab),
a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a
key role in the ability of HIV to enter and infect healthy T-cells. The
CCR5 receptor is also implicated in tumor metastasis and in immune-mediated
illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has
successfully completed a Phase 3 pivotal trial with PRO 140 in combination with
standard anti-retroviral therapies in HIV-infected treatment-experienced
patients. The Company plans to seek FDA approval for PRO 140 in combination
therapy and plans to complete the filing of a Biological License Application
(BLA) in the first quarter of 2019 for that indication. CytoDyn is also
conducting a Phase 3 investigative trial with PRO 140 as a once-weekly
monotherapy for HIV-infected patients, and plans to initiate a
registration-directed study of PRO 140 monotherapy indication, which if
successful, could support a label extension. Clinical results to date from
multiple trials have shown that PRO 140 can significantly reduce viral burden in
people infected with HIV with no reported drug-related serious adverse events
(SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO
140 monotherapy can prevent viral escape in HIV-infected patients, with some
patients on PRO 140 monotherapy remaining virally suppressed for more than four
years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the
prevention of GvHD and expects to initiate clinical trials with PRO 140 in
metastatic triple-negative breast cancer in 2018. For more information, visit
the company’s website at www.CytoDyn.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
QualityStocks has received compensation from CytoDyn Inc.
for providing certain investor relations, marketing and social media services,
including the preparation of this report, and expects to receive additional
compensation for such services in the future. This compensation includes a
monthly program fee.
No comments:
Post a Comment